The global surface protein gp 120 market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in March 2021, Gilead Sciences Inc. and Merck have jointly entered into a partnership to co-develop and co-commercialize the long-acting and investigational treatment combinations of Lenacapvir and Islatravir in HIV. According to the agreement, Gilead and Merck Sharp & Dohme (Merck &Co) will share operational responsibilities as well as development, marketing costs, and future revenues. According to Merck &Co, this partnership aims to save and improve lives and enable advanced care for people living with HIV.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/surface-protein-gp-120-market
Moreover, in January 2021, ViiV Healthcare received US Food and Drug Administration (FDA) approval for the use of Canbenuva. Cabenuva is an injectable drug developed by ViiV Healthcare, used for the treatment of HIV infections in adults. Furthermore, in December 2020, Gilead Sciences Inc has announced the $1.4 million for Gilead Asia Pacific Rainbow Grant Program, in the Asia Pacific. This program aimed to improve the public-private partnerships in the Asia-Pacific region, to resolve the challenges faced by HIV-infected patients. Similarly, in September 2019, Merck Sharp & Dohme Corp (Merck &Co) has been granted US Food and Drug Administration (FDA) approval for Peifeltro and Delstrigo combination drugs. These combination drugs are used for the treatment of HIV Infection in Adults. Thus, key approvals, strategic collaborations, and grants are anticipated to drive the growth of the global surface protein gp 120 market over the forecast period (2022-2028)
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
Segment Covered-
o By Type
o By Application
Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
Competitive Landscape- GlaxoSmithKline Plc., ViiV Healthcare, Gilead services, Inc., and more among others
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Surface Protein gp 120 Market Report Segment
By Type
- DS-003
- BMD-104
- HNG-156
- M-48U1
By Application
- Hospitals
- Clinics
A full report of Surface Protein GP 120 Market is available at: https://www.omrglobal.com/industry-reports/surface-protein-gp-120-market
Surface Protein GP 120 Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AbbVie Inc.
- Arena Pharmaceuticals, Inc
- AbbVie Inc.
- Acceleron Pharma, Inc.
- ACROBiosystems
- Eli Lilly &Co.
- Genentech, Inc. (F. Hoffmann-La Roche AG)
- Janssen Global Services, LLC (Johnson & Johnson Services, Inc.)
- Novartis AG
- Mylan N.V
